Earnings News
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

MEDNAX Q2 Profit Grows; Announces Acquisition Of Loudoun Anesthesia Associates

RELATED NEWS
Trade MD now with 
7/31/2012 6:26 AM ET

MEDNAX, Inc. (MD: Quote) posted second quarter profit of $60.54 million or $1.22 per share, up from $55.94 million or $1.15 per share last year.

On average, 15 analysts polled by Thomson Reuters expected the company to report earnings of $1.19 per share. Analysts' estimates typically exclude special items.

Net patient service revenue rose to $449.53 million from $393.4 million in the comparable period a year ago. Analysts expected revenues of $437.33 million.

MEDNAX's revenue growth attributable to contributions from recently acquired practices was 10.4 percent, while same-unit revenue grew by 3.9 percent for the quarter, compared to last year.

Looking forward to the third quarter, MEDNAX expects earnings will be in a range of $1.25 to $1.30 per share. This range assumes that total same-unit revenue for the three months ended September 30, 2012 will grow by 1.0 percent to 3.0 percent from the prior-year period. Analysts expect earnings of $1.26 per share.

Separately, MEDNAX announced the acquisition of Loudoun Anesthesia Associates, a physician group practice that provides anesthesia services at Inova Loudoun Hospital and Inova Loudoun Ambulatory Surgery Center in Leesburg.

This practice was acquired for cash and the deal is anticipated to be immediately accretive to earnings. No additional terms of the transactions were disclosed.

The physicians joining as a result of this transaction will now be part of MEDNAX's American Anesthesiology division.

Register
To receive FREE breaking news email alerts for Mednax Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.